Subscribe to our press releases
ChromoGenics announces recalculated terms for previous issued stock options (TO2) (translation of Swedish PM from February 21)
As a result of the recent rights issue the terms for the stock options (TO2) issued 2018 with strike 10-31 January 2020 will be recalculated. After recalculation every stock option of series TO2 will warrant a right to buy 1,62 shares to a price of 2,17 SEK. Maximally 30.655.062 new shares will be issued from the stock options which corresponds to a dilution by 17,7 percent. Bu full utilization of the options an additional capital of 66,4 MSEK will be brought to the company will.
Jerker Lundgren, CEO
Lars Ericsson, CFO and Head of Communications
Tel: +46 (0)18 430 0430
Certified Adviser: G&W Fondkommission, e-mail: firstname.lastname@example.org, tel.: +46 (0) 8 503 000 50
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
ChromoGenics offers dynamic glass with controllable heat- and light transmission and static glass with world leading performance. The company’s unique technology ConverLight® provides sustainable solar control for increased indoor comfort and energy efficiency. ConverLight also contributes to Green Building certifications. In 2016 the company started commercial sales to real estate projects in Scandinavia.
ChromoGenics is located in Uppsala, Sweden, and the technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. ChromoGenics share (CHRO) is listed on Nasdaq First North Stockholm with G&W Fondkommission as Certified Adviser.